Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-06-08
2003-06-03
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C424S239100, C435S069700, C435S252700, C530S350000, C530S412000, C530S825000
Reexamination Certificate
active
06573241
ABSTRACT:
BACKGROUND OF THE INVENTION
Nightly snoring is not only a psychosocial problem. This disorder represents a risk factor for diseases of the cardiovascular system such as hypertension (Kleitmann, 1963; Lugaresi et al., 1983; Hoffstein et al., 1991) and myocardial (Waller and Bhopal, 1989; Koskenvuo et al., 1985) as well as central ischemia (Koskenvuo et al., 1987). Moreover, patients with constricted respiratory tract are especially at risk of developing a sleep apnea which goes hand-in-hand with an increased mortality (He et al., 1988; Hoch et al., 1986).
The soft palate is comprised of the striated muscles
M. tensor veli palatini, M. pterygoideus, M. genioglossus, M. geniohyoideus
, and
M. sternohyoideus
. When breathing in, some of these muscles are activated. The degree of activation depends moreover on some other factors which have not yet been elucidated in detail. A disruption of the interaction of the muscles can cause snoring. One reason for snoring is an increased tone of the
M. tensor veli palatini
during the deep sleep phase. In the REM phase, the muscle tone is lowered and snoring decreases or ceases (Lugaresi et al. 1994). However, when the tension of the muscles is increased, a sounding board is generated which is caused to vibrate as a result of the breathing air passing it. When the vibration frequency is above 20-30 Hz, it becomes audible. The higher the frequency of the vibrations, the higher the pitch of the snoring. The frequency depends on the tension of the muscles: a more strongly tensioned muscle vibrates at a higher frequency than a slightly tensioned one; a relaxed muscle does not vibrate. The volume of snoring correlates with the vibration amplitude which is determined by the speed of the breathing air passing by.
When the pathologically tensioned striated muscles are paralyzed with a long-acting muscle relaxant, the increased muscle tensions during this deep sleep phase are suppressed, and snoring does not occur.
Botulinum toxins of the type A, B, C1, D, E, F, and G (BoNT/X) are strongly effective neurotoxins which induce paralysis of the striated muscles lasting for several weeks (Ahnert-Hilger and Bigalke, 1995). The cause of paralysis is an inhibition of the acetylcholine release from the nerve ends supplying the muscles. The toxins are proteins and are comprised of two subunits of different size which are covalently bonded to one another with a total weight of M
R
150,000. Some of these neurotoxins are embedded in a complex (total weight: M
R
900,000) which is comprised of hemagglutinins and non-toxic proteins (Inoue et al., 1995). Exclusively the presence of the neurotoxin is required for the muscle paralysis, which neurotoxin bonds with its larger chain, i.e., the C-terminal subunit of the toxin, to receptors which are only present at nerve cells. By means of a receptor-induced endocytosis, the toxin is endocyted by the nerve cells. Here, the lighter chains, the N-terminal subunits, cleave cell-own proteins, which play a key role in the fusion of transmitter-containing vesicles with the plasma membrane (Schiavo and Montecucco, 1997). As a result of cleavage the fusion is suppressed, and the release of the transmitter is blocked: the muscle can no longer contract. Several of the cell-own proteins (fusion proteins), which are present in the membranes of secretory vesicles and/or in the plasma membrane, take part in the secretion process or the release. They can also be present in the cytosol. These proteins include SNAP 25, synaptobrevin (VAMP) and syntaxin, respectively, their isomeric forms. These proteins form the so-called fusion complex which fixes the secretory vesicles to the inner side of the plasma membrane. The fixation is preceded by membrane fusion, which is triggered by a tension-inducing Ca
++
influx. As a result of the inactivation of only one of the fusion proteins, for example, by proteolytic cleavage, the formation of the fusion complex is prevented. The fusion proteins are the target molecules of the light chains of the above-mentioned neurotoxins. For example, BoNT/B, D, F and G cleave VAMP, while BoNT/A, C1 and E deactivate SNAP 25, and Syntaxin is cut by BoNT/C1. VAMP is moreover inactivated by tetanus toxin (TeNT), a poison which also belongs to the group of Clostridia neurotoxins (Ahnert-Hilger and Bigalke, 1995).
BoNT/A is already used therapeutically for the treatment of different forms of local, often very painful, muscle tensions that impair the patient greatly, for example, Torticollis spasmodicus, Blepharospasmus, various spasticities and the like (Cardoso and Jankovic, 1995). The toxin is injected into the respective muscle. After a few days, the muscle is paralyzed. The patient is pain-free and can again fulfill his daily tasks. Undesirable side effects occur rarely and are fully reversible, as are the desired effects.
SUMMARY OF THE INVENTION
An elimination of snoring could be achieved if it were possible to suppress the increased tone of the palate muscles in the deep sleep phase. Since the tone increase is caused by an increased acetylcholine release, the blockage of the release can cause the muscles to relax and can eliminate snoring.
The object of the invention is now solved by therapeutic agents for suppressing snoring noises which are characterized by a Clostridium toxin and/or a complex of this toxin or a contents of toxin or complex.
Accordingly, the invention relates to a therapeutic agent for suppressing snoring noises which is characterized by a high-purity Clostridium toxin BoNT/A.
Accordingly, BoNT/A can be injected in minimal dosage into the respective muscle of the soft palate, for example, into the
M. tensor veli palatini
. With the same injection technology the spasmodic dysphonia is already treated which is also the result of an increased tone of certain muscles of the soft palate (Schönweiler et al., 1998).
Moreover, the invention concerns a therapeutic agent for suppressing snoring noises which is characterized by a high-purity Clostridium toxin BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F and/or BoNT/G.
Moreover, the invention relates to a therapeutic agent for suppressing snoring noises which is characterized by a high-purity Clostridium toxin TeNT.
Moreover, the invention relates to a therapeutic agent for suppressing snoring noises, which is characterized by
(i) a hybrid protein as the Clostridium toxin, comprised of a light subunit of a Clostridium toxin of the following group and of a heavy subunit of a different Clostridium toxin of the same following group, comprised of: BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F, BoNT/G and TeNT; or
(ii) by a mixture of hybrid proteins according to (i).
Moreover, the invention relates to a therapeutic agent which is characterized by a complex, comprising
(i) a Clostridium toxin or a hybridprotein and
(ii) one or more therapeutically well-tolerated hemagglutinins and/or one or more pharmaceutically well-tolerated non-toxic proteins.
Moreover, the invention relates to a therapeutic agent which is characterized by a complex of the wild type.
Moreover, the invention relates to a therapeutic agent which is characterized in that the Clostridium toxin is a recombinant protein.
Moreover, the invention relates to a therapeutic agent which is characterized in that the Clostridium toxin is a lyophilized protein.
Moreover, the invention relates to a therapeutic agent which is characterized in that it is present as an aqueous solution, in particular, an aqueous injection solution.
Moreover, the invention relates to a therapeutic agent which is characterized in that the Clostridium toxin or its complex is present as a physiological saline solution.
Finally, the invention relates to a therapeutic agent which is characterized by liposomes as carriers for the Clostridium toxin or its complex.
The administration of the pure neurotoxin is preferred as compared to the injection of the complex because only the neurotoxin provides the activity. Since the neurotoxin has a smaller molecular weight than the complex, it is distributed by diffusion more quickl
Bigalke Hans
Frevert Jürgen
BioteCon Gesellschaft für bio-technologische Entwicklung und Con
Huckett Gudrun E.
Kam Chih-Min
Low Christopher S. F.
LandOfFree
Therapeutic agent for the suppression of snoring noises does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for the suppression of snoring noises, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for the suppression of snoring noises will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3110286